Calistoga appoints new chief business officer
This article was originally published in Scrip
Calistoga Pharmaceuticals, a US company focused on the development of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, has named Clifford Stocks chief business officer. He has more than 20 years' experience in the biotech industry, including 15 years at Icos, where he served as an executive officer and vice-president of business development.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.